Other Income and Expense Items (Tables)

12 Months Ended

Jun. 30, 2025

Other Income and Expense Items [Abstract]

Schedule of Other income

(a) Other income

	30 June 2025 $		30 June 2024 $		30 June 2023 $
Interest		888,196		50,484		145,035
Research and Development tax incentive		9,368,544		1,292,578		5,917,484
		10,256,740		1,343,062		6,062,519

Schedule of Other Losses

(b) Other losses

	Notes	30 June 2025 $			30 June 2024 $			30 June              2023                   $
Fair value adjustment on financing agreements			(489,787	)		366,719			-
Net foreign exchange gains/(losses)			138,141			94,964			(257,251	)
Loss on sale of available-for-sale assets	6(a)		-			(1,687,791	)		-
			(351,646	)		(1,226,108	)		(257,251	)

Schedule of Breakdown of Expenses by Nature

(c) Breakdown of expenses by nature

	Notes	30 June 2025 $		30 June 2024 $		30 June 2023 $
General and administrative expenses
Accounting and audit			957,895		845,818		1,205,015
Consulting			286,138		95,179		1,117,981
Depreciation			7,331		7,534		6,553
Employee benefits			10,120,149		9,448,779		6,149,314
Insurance			105,762		359,209		685,413
Investor relations			313,671		323,588		565,032
Legal			656,036		164,754		959,258
Listing and share registry			190,795		193,797		164,116
Patent costs			205,017		204,163		205,709
Travel and entertainment			808,546		427,676		648,532
Other			986,673		968,749		524,125
			14,638,013		13,039,246		12,231,048
Research and development
Amortization			2,588,306		3,118,752		3,289,979
AVb6 Integrin (TRIMT)			1,876,983		993,645		3,735,540
Consulting Fees R&D			930,292		929,229		2,441,106
hu PSA Anti-body (Diaprost)			2,925,445		298,312		1,571,795
Impairment	6(b)(viii)		-		1,478,892		3,100,000
R&D Ventures			5,989,964		3,931,541		324,888
NanoMab			7,185,000		6,501,174		6,090,209
Neoindicate			437,400		529,424		538,906
Pharma15			-		-		10,724
Pivalate - Imperial			5,184,136		3,962,355		1,195,120
UCLA			226,063		1,253,493		333,242
Other			171,605		89,450		-
			27,515,194		23,086,267		22,631,509